Another study showed that combining low-toxicity IFN (IFN-γ, IFN-β) with TLR agonists increased M1 induction by up to 100-fold, suggesting novel TLR-targeted strategies for tumor immunotherapy (107). Here, IFNG is linked to neoplasm.